1
|
Saleki K, Razi S, Rezaei N. Infection and Immunity. Clin Immunol 2023. [DOI: 10.1016/b978-0-12-818006-8.00007-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
|
2
|
Smirnova NS, Kostarnoy AV, Kondratev AV, Gancheva PG, Grumov DA, Gintsburg AL. Diagnostic Value of IgA Antibody Measurement in Tick-Borne Spotted Fever (Astrakhan Rickettsial Fever). Microbiol Spectr 2022; 10:e0168721. [PMID: 35467375 PMCID: PMC9241626 DOI: 10.1128/spectrum.01687-21] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2021] [Accepted: 03/25/2022] [Indexed: 12/29/2022] Open
Abstract
Tick-borne spotted fevers caused by Rickettsia occur worldwide. The symptoms of this bacterial infection are similar to those of viral infection, and thus, diagnostic accuracy has special clinical importance. One of the commonly used methods for the diagnosis of tick-borne spotted fever is enzyme-linked immunosorbent assay (ELISA), which is based on estimation of the presence of specific IgM antibodies in blood. However, IgA analysis has not been used for the diagnosis of rickettsial diseases thus far. We investigated the diagnostic value of IgA antibody determination using patient sera collected in the Astrakhan region of Russia, where an isolated site of Astrakhan rickettsial fever (ARF) caused by Rickettsia conorii subsp. caspia is located. Our investigation was performed on serum samples collected from 185 patients diagnosed with Astrakhan rickettsial fever from May to October 2019. Western blot analysis revealed that specific IgA antibodies, as well as IgM antibodies, from patient sera bind to high-molecular-weight pathogen proteins with similar masses. The obtained data show that the determination of IgM alone allows for serological confirmation of diagnosis in only 46.5% of cases but that the determination of both IgM and IgA increases this rate to 66.5%. Taken together, the findings show an important diagnostic value of IgA evaluation for tick-borne spotted fever rickettsiosis. IMPORTANCE Tick-borne spotted fevers caused by Rickettsia occur worldwide. The symptoms of this bacterial infection are similar to the symptoms of viral infection, and thus, diagnostic accuracy has special clinical importance. The most serious spotted fever group rickettsiosis is Rocky Mountain fever in the United States, which is caused by Rickettsia rickettsii, and disease complications can lead to hemiparesis, blindness, or amputation. Rickettsia conorii subsp. caspia causes a rickettsial spotted fever named Astrakhan rickettsial fever (ARF). One of the commonly used methods for the diagnosis of tick-borne spotted fevers is ELISA, which is based on estimation of the presence of specific IgM antibodies in blood, though IgA has not been used for the diagnosis of rickettsial diseases thus far. In this study, we showed that both IgA and IgM should be analyzed in the blood serum samples of patients to significantly enhance the accuracy of diagnostics of tick-borne spotted fever rickettsiosis.
Collapse
Affiliation(s)
- Nina S. Smirnova
- Laboratory of Ecology of Rickettsia, N. F. Gamaleya National Research Center of Epidemiology and Microbiology, Moscow, Russia
| | - Alexey V. Kostarnoy
- Laboratory of Ecology of Rickettsia, N. F. Gamaleya National Research Center of Epidemiology and Microbiology, Moscow, Russia
| | - Alexey V. Kondratev
- Laboratory of Ecology of Rickettsia, N. F. Gamaleya National Research Center of Epidemiology and Microbiology, Moscow, Russia
| | - Petya G. Gancheva
- Laboratory of Immunobiotechnology, N. F. Gamaleya National Research Center of Epidemiology and Microbiology, Moscow, Russia
| | - Daniil A. Grumov
- Laboratory of Ecology of Rickettsia, N. F. Gamaleya National Research Center of Epidemiology and Microbiology, Moscow, Russia
| | - Alexander L. Gintsburg
- Laboratory of Gene Engineering of Pathogenic Microorganisms, N. F. Gamaleya National Research Center of Epidemiology and Microbiology, Moscow, Russia
| |
Collapse
|
3
|
Bharucha T, Ayhan N, Pastorino B, Rattanavong S, Vongsouvath M, Mayxay M, Changthongthip A, Sengvilaipaseuth O, Phonemixay O, Pommier JD, Gorman C, Zitzmann N, Newton PN, de Lamballerie X, Dubot-Pérès A. Immunoglobulin M seroneutralization for improved confirmation of Japanese encephalitis virus infection in a flavivirus-endemic area. Trans R Soc Trop Med Hyg 2022; 116:1032-1042. [PMID: 35593182 PMCID: PMC9623734 DOI: 10.1093/trstmh/trac036] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2021] [Revised: 01/21/2022] [Accepted: 03/28/2022] [Indexed: 01/19/2023] Open
Abstract
BACKGROUND The mainstay of diagnostic confirmation of acute Japanese encephalitis (JE) involves detection of anti-JE virus (JEV) immunoglobulin M (IgM) by enzyme-linked immunosorbent assay (ELISA). Limitations in the specificity of this test are increasingly apparent with the introduction of JEV vaccinations and the endemicity of other cross-reactive flaviviruses. Virus neutralization testing (VNT) is considered the gold standard, but it is challenging to implement and interpret. We performed a pilot study to assess IgG depletion prior to VNT for detection of anti-JEV IgM neutralizing antibodies (IgM-VNT) as compared with standard VNT. METHODS We evaluated IgM-VNT in paired sera from anti-JEV IgM ELISA-positive patients (JE n=35) and negative controls of healthy flavivirus-naïve (n=10) as well as confirmed dengue (n=12) and Zika virus (n=4) patient sera. IgM-VNT was subsequently performed on single sera from additional JE patients (n=76). RESULTS Anti-JEV IgG was detectable in admission serum of 58% of JE patients. The positive, negative and overall percentage agreement of IgM-VNT as compared with standard VNT was 100%. A total of 12/14 (86%) patient samples were unclassified by VNT and, with sufficient sample available for IgG depletion and IgG ELISA confirming depletion, were classified by IgM-VNT. IgM-VNT enabled JE case classification in 72/76 (95%) patients for whom only a single sample was available. CONCLUSIONS The novel approach has been readily adapted for high-throughput testing of single patient samples and it holds promise for incorporation into algorithms for use in reference centres.
Collapse
Affiliation(s)
| | - Nazli Ayhan
- Unité des Virus Émergents, Aix-Marseille Univ-IRD 190-Inserm 1207, Marseille, France
| | - Boris Pastorino
- Unité des Virus Émergents, Aix-Marseille Univ-IRD 190-Inserm 1207, Marseille, France
| | - Sayaphet Rattanavong
- Lao-Oxford-Mahosot Hospital-Wellcome Trust-Research Unit, Microbiology Laboratory, Mahosot Hospital, Vientiane, Lao PDR
| | - Manivanh Vongsouvath
- Lao-Oxford-Mahosot Hospital-Wellcome Trust-Research Unit, Microbiology Laboratory, Mahosot Hospital, Vientiane, Lao PDR
| | - Mayfong Mayxay
- Lao-Oxford-Mahosot Hospital-Wellcome Trust-Research Unit, Microbiology Laboratory, Mahosot Hospital, Vientiane, Lao PDR,Institute of Research and Education Development, University of Health Sciences, Ministry of Health, Vientiane, Lao PDR,Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK
| | - Anisone Changthongthip
- Lao-Oxford-Mahosot Hospital-Wellcome Trust-Research Unit, Microbiology Laboratory, Mahosot Hospital, Vientiane, Lao PDR
| | - Onanong Sengvilaipaseuth
- Lao-Oxford-Mahosot Hospital-Wellcome Trust-Research Unit, Microbiology Laboratory, Mahosot Hospital, Vientiane, Lao PDR
| | - Ooyanong Phonemixay
- Lao-Oxford-Mahosot Hospital-Wellcome Trust-Research Unit, Microbiology Laboratory, Mahosot Hospital, Vientiane, Lao PDR
| | - Jean-David Pommier
- Epidemiology and Public Health Unit, Institut Pasteur du Cambodge, Phnom Penh, Cambodia,Institut Pasteur, Biology of Infection Unit, Paris, France,Inserm U1117, Paris, France,Intensive Care Department, University Hospital of Guadeloupe, France
| | | | - Nicole Zitzmann
- Department of Biochemistry, University of Oxford, Oxford, UK
| | - Paul N Newton
- Lao-Oxford-Mahosot Hospital-Wellcome Trust-Research Unit, Microbiology Laboratory, Mahosot Hospital, Vientiane, Lao PDR,Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK
| | - Xavier de Lamballerie
- Unité des Virus Émergents, Aix-Marseille Univ-IRD 190-Inserm 1207, Marseille, France
| | - Audrey Dubot-Pérès
- Lao-Oxford-Mahosot Hospital-Wellcome Trust-Research Unit, Microbiology Laboratory, Mahosot Hospital, Vientiane, Lao PDR,Unité des Virus Émergents, Aix-Marseille Univ-IRD 190-Inserm 1207, Marseille, France,Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK
| |
Collapse
|
4
|
Manuylov V, Burgasova O, Borisova O, Smetanina S, Vasina D, Grigoriev I, Kudryashova A, Semashko M, Cherepovich B, Kharchenko O, Kleymenov D, Mazunina E, Tkachuk A, Gushchin V. Avidity of IgG to SARS-CoV-2 RBD as a Prognostic Factor for the Severity of COVID-19 Reinfection. Viruses 2022; 14:v14030617. [PMID: 35337024 PMCID: PMC8949074 DOI: 10.3390/v14030617] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2022] [Revised: 03/07/2022] [Accepted: 03/12/2022] [Indexed: 12/19/2022] Open
Abstract
The avidity index (AI) of IgG to the RBD of SARS-CoV-2 was determined for 71 patients with a mild (outpatient) course of COVID-19, including 39 primarily and 36 secondarily reinfected, and 92 patients with a severe (hospital) course of COVID-19, including 82 primarily and 10 secondarily infected. The AI was shown to correlate with the severity of repeated disease. In the group of outpatients with a mild course, the reinfected patients had significantly higher median AIs than those with primary infections (82.3% vs. 37.1%, p < 0.0001). At the same time, in patients with a severe course of COVID-19, reinfected patients still had low-avidity antibodies (median AI of 28.4% vs. 25% in the primarily infected, difference not significant, p > 0.05). This suggests that the presence of low-avidity IgG to RBD during reinfection is a negative prognostic factor, in which a patient’s risk of developing COVID-19 in a severe form is significantly increased. Thus, patients with IgG of low avidity (AI ≤ 40%) had an 89 ± 20.5% chance of a severe course of recurrent COVID-19, whereas the detection of high-avidity antibodies (AI ≥ 50%) gave a probability of 94 ± 7.9% for a mild course of recurrent disease (p < 0.05).
Collapse
Affiliation(s)
- Victor Manuylov
- Gamaleya National Research Center for Epidemiology and Microbiology, 123098 Moscow, Russia; (O.B.); (D.V.); (I.G.); (M.S.); (D.K.); (E.M.); (A.T.); (V.G.)
- MedipalTech LLC, 141981 Dubna, Russia
- Correspondence: ; Tel.: +7-968-4040-955
| | - Olga Burgasova
- Gamaleya National Research Center for Epidemiology and Microbiology, 123098 Moscow, Russia; (O.B.); (D.V.); (I.G.); (M.S.); (D.K.); (E.M.); (A.T.); (V.G.)
- Medical Institute, Peoples Friendship University of Russia (RUDN University), 117198 Moscow, Russia
| | - Olga Borisova
- Mechnikov Research Institute for Vaccines and Sera, 105064 Moscow, Russia; (O.B.); (A.K.); (B.C.); (O.K.)
| | | | - Daria Vasina
- Gamaleya National Research Center for Epidemiology and Microbiology, 123098 Moscow, Russia; (O.B.); (D.V.); (I.G.); (M.S.); (D.K.); (E.M.); (A.T.); (V.G.)
| | - Igor Grigoriev
- Gamaleya National Research Center for Epidemiology and Microbiology, 123098 Moscow, Russia; (O.B.); (D.V.); (I.G.); (M.S.); (D.K.); (E.M.); (A.T.); (V.G.)
| | - Alexandra Kudryashova
- Mechnikov Research Institute for Vaccines and Sera, 105064 Moscow, Russia; (O.B.); (A.K.); (B.C.); (O.K.)
| | - Maria Semashko
- Gamaleya National Research Center for Epidemiology and Microbiology, 123098 Moscow, Russia; (O.B.); (D.V.); (I.G.); (M.S.); (D.K.); (E.M.); (A.T.); (V.G.)
| | - Bogdan Cherepovich
- Mechnikov Research Institute for Vaccines and Sera, 105064 Moscow, Russia; (O.B.); (A.K.); (B.C.); (O.K.)
| | - Olga Kharchenko
- Mechnikov Research Institute for Vaccines and Sera, 105064 Moscow, Russia; (O.B.); (A.K.); (B.C.); (O.K.)
| | - Denis Kleymenov
- Gamaleya National Research Center for Epidemiology and Microbiology, 123098 Moscow, Russia; (O.B.); (D.V.); (I.G.); (M.S.); (D.K.); (E.M.); (A.T.); (V.G.)
| | - Elena Mazunina
- Gamaleya National Research Center for Epidemiology and Microbiology, 123098 Moscow, Russia; (O.B.); (D.V.); (I.G.); (M.S.); (D.K.); (E.M.); (A.T.); (V.G.)
| | - Artem Tkachuk
- Gamaleya National Research Center for Epidemiology and Microbiology, 123098 Moscow, Russia; (O.B.); (D.V.); (I.G.); (M.S.); (D.K.); (E.M.); (A.T.); (V.G.)
| | - Vladimir Gushchin
- Gamaleya National Research Center for Epidemiology and Microbiology, 123098 Moscow, Russia; (O.B.); (D.V.); (I.G.); (M.S.); (D.K.); (E.M.); (A.T.); (V.G.)
| |
Collapse
|
5
|
Opi DH, Kurtovic L, Chan JA, Horton JL, Feng G, Beeson JG. Multi-functional antibody profiling for malaria vaccine development and evaluation. Expert Rev Vaccines 2021; 20:1257-1272. [PMID: 34530671 DOI: 10.1080/14760584.2021.1981864] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
INTRODUCTION A vaccine would greatly accelerate current global efforts toward malaria elimination. While a partially efficacious vaccine has been achieved for Plasmodium falciparum, a major bottleneck in developing highly efficacious vaccines is a lack of reliable correlates of protection, and the limited application of assays that quantify functional immune responses to evaluate and down-select vaccine candidates in pre-clinical studies and clinical trials. AREAS COVERED In this review, we describe the important role of antibodies in immunity against malaria and detail the nature and functional activities of antibodies against the malaria-causing parasite. We highlight the growing understanding of antibody effector functions against malaria and in vitro assays to measure these functional antibody responses. We discuss the application of these assays to quantify antibody functions in vaccine development and evaluation. EXPERT OPINION It is becoming increasingly clear that multiple antibody effector functions are involved in immunity to malaria. Therefore, we propose that evaluating vaccine candidates needs to move beyond individual assays or measuring IgG magnitude alone. Instead, vaccine evaluation should incorporate the full breadth of antibody response types and harness a wider range of assays measuring functional antibody responses. We propose a 3-tier approach to implementing assays to inform vaccine evaluation.
Collapse
Affiliation(s)
- D Herbert Opi
- Life Sciences, Burnet Institute, Melbourne, Australia.,Department of Immunology and Pathology, Monash University, Melbourne, Australia.,Department of Medicine, The Doherty Institute, The University of Melbourne, Melbourne, Australia
| | - Liriye Kurtovic
- Life Sciences, Burnet Institute, Melbourne, Australia.,Department of Immunology and Pathology, Monash University, Melbourne, Australia
| | - Jo-Anne Chan
- Life Sciences, Burnet Institute, Melbourne, Australia.,Department of Immunology and Pathology, Monash University, Melbourne, Australia.,Department of Medicine, The Doherty Institute, The University of Melbourne, Melbourne, Australia
| | - Jessica L Horton
- Life Sciences, Burnet Institute, Melbourne, Australia.,Department of Medicine, The Doherty Institute, The University of Melbourne, Melbourne, Australia
| | - Gaoqian Feng
- Life Sciences, Burnet Institute, Melbourne, Australia.,Department of Medicine, The Doherty Institute, The University of Melbourne, Melbourne, Australia
| | - James G Beeson
- Life Sciences, Burnet Institute, Melbourne, Australia.,Department of Immunology and Pathology, Monash University, Melbourne, Australia.,Department of Medicine, The Doherty Institute, The University of Melbourne, Melbourne, Australia.,Department of Microbiology, Monash University, Clayton, Australia
| |
Collapse
|
6
|
Bharucha T, Shearer FM, Vongsouvath M, Mayxay M, de Lamballerie X, Newton PN, Zitzmann N, Gould E, Dubot-Pérès A. A need to raise the bar - A systematic review of temporal trends in diagnostics for Japanese encephalitis virus infection, and perspectives for future research. Int J Infect Dis 2020; 95:444-56. [PMID: 32205287 DOI: 10.1016/j.ijid.2020.03.039] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2020] [Revised: 03/09/2020] [Accepted: 03/15/2020] [Indexed: 12/14/2022] Open
Abstract
Japanese encephalitis virus (JEV) remains a leading cause of neurological infection in Asia. A systematic review identified 20,212 published human cases of laboratory-confirmed JEV infections from 205 studies. 15,167 (75%) of cases were confirmed with the lowest confidence diagnostic test, i.e., level 3 or 4, or level 4. Only 109 (53%) of the studies reported contemporaneous testing for dengue-specific antibodies. A fundamental pre-requisite for the control of JE is lacking — that of a simple and specific diagnostic procedure that can be adapted for point-of-care tests and readily used throughout JE endemic regions of the world.
Objective Japanese encephalitis virus infection (JE) remains a leading cause of neurological disease in Asia, mainly involving individuals living in remote areas with limited access to treatment centers and diagnostic facilities. Laboratory confirmation is fundamental for the justification and implementation of vaccination programs. We reviewed the literature on historical developments and current diagnostic capability worldwide, to identify knowledge gaps and instill urgency to address them. Methods Searches were performed in Web of Science and PubMed using the term 'Japanese encephalitis' up to 13th October 2019. Studies reporting laboratory-confirmed symptomatic JE cases in humans were included, and data on details of diagnostic tests were extracted. A JE case was classified according to confirmatory levels (Fischer et al., 2008; Campbell et al., 2011; Pearce et al., 2018; Heffelfinger et al., 2017), where level 1 represented the highest level of confidence. Findings 20,212 published JE cases were identified from 205 studies. 15,167 (75%) of these positive cases were confirmed with the lowest-confidence diagnostic tests (level 3 or 4, or level 4). Only 109 (53%) of the studies reported contemporaneous testing for dengue-specific antibodies. Conclusion A fundamental pre-requisite for the control of JEV is lacking — that of a simple and specific diagnostic procedure that can be adapted for point-of-care tests and readily used throughout JE-endemic regions of the world.
Collapse
|
7
|
Bouthry E, Hervé A, Brichler S, Poveda JD, Roque-Afonso AM, Vauloup-Fellous C. Evaluation and optimisation of commercial Zika IgG avidity assay. J Clin Virol 2020; 124:104260. [PMID: 32035400 DOI: 10.1016/j.jcv.2020.104260] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2019] [Revised: 01/03/2020] [Accepted: 01/08/2020] [Indexed: 10/25/2022]
Abstract
BACKGROUND ZIKV infection has potentially severe consequences particularly in fetuses/newborns born to mothers that were infected early in pregnancy. Diagnosis relies on the detection of ZIKV IgM that can also be detected due to cross reactivity or to nonspecific polyclonal activation of the immune system. Therefore, in case of ZIKV IgM detection, identification of a recent infection can be of major importance for the optimal management of pregnant women. OBJECTIVE This study evaluates the performances of a commercially available assay to measure ZIKV-IgG avidity. STUDY DESIGN A total of 110 serum or plasma samples collected from symptomatic or asymptomatic patients living or returning from a ZIKV endemic area were classified according to epidemiological and clinical information, and to serology and molecular assays' results. Samples were tested with the IgG ZIKV Avidity Test (DIA.PRO®) according to manufacturer's instruction and with a modified protocol. RESULTS By using the manufacturer's Avidity Index cut-off, distinction between recent and past infection was unclear with similar AIs in the two situations (p = 0.8872). Sensitivity and specificity in identifying recent infection were poor, 67.3 % and 4.5 % respectively. By using a modified protocol, a better discrimination was observed with significant differences between mean AIs (p = 0.0318), and with higher sensitivity and specificity, respectively 87.8 % and 100 %. CONCLUSION Our results highlight that IgG ZIKV Avidity Test DIA.PRO® assay is not reliable enough to be used in clinical practice without modifications.
Collapse
Affiliation(s)
- Elise Bouthry
- AP-HP, Hôpital Paul Brousse, Department of Virology, WHO Rubella NRL, 94804, Villejuif, France; Groupe de Recherche sur les Infections pendant la Grossesse (GRIG), France.
| | - Anaïs Hervé
- AP-HP, Hôpital Paul Brousse, Department of Virology, WHO Rubella NRL, 94804, Villejuif, France
| | - Ségolène Brichler
- AP-HP, Hôpital Avicenne, Department of Virology, 93000, Bobigny, France
| | | | - Anne-Marie Roque-Afonso
- AP-HP, Hôpital Paul Brousse, Department of Virology, WHO Rubella NRL, 94804, Villejuif, France; Univ Paris-Sud, INSERM U1193, Villejuif, 94804, France
| | - Christelle Vauloup-Fellous
- AP-HP, Hôpital Paul Brousse, Department of Virology, WHO Rubella NRL, 94804, Villejuif, France; Univ Paris-Sud, INSERM U1193, Villejuif, 94804, France; Groupe de Recherche sur les Infections pendant la Grossesse (GRIG), France
| |
Collapse
|
8
|
Pérez-Olmeda M, Sánchez-Seco MP, Vázquez A, Balfagón P, de la Fuente J, Murillo MÁ, Minguito T, de Ory F. Evaluation of the LIAISON XL Zika Capture IgM II for the Diagnosis of Zika Virus Infections. Viruses 2020; 12:E69. [PMID: 31936013 DOI: 10.3390/v12010069] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2019] [Revised: 12/27/2019] [Accepted: 01/03/2020] [Indexed: 11/29/2022] Open
Abstract
The aim of this study is to evaluate the performance characteristics of the LIAISON XL Zika Capture IgM II. For this purpose we tested 128 samples obtained from recent infections caused by the Zika (ZIKV; 74 samples), dengue (DENV; 10 samples), chikungunya (CHIK V; 11 samples), rubella (RUBV; 10 samples) and measles (MeV; 10 samples) viruses, as well as human parvovirus B19 (HPVB19; 13 samples). The results of the assay under evaluation are compared with those obtained from an indirect immunofluorescence (IIF) assay, and the discrepancies are resolved by considering other laboratory results (PCR and a plaque-reduction neutralization test). The LIAISON showed excellent sensitivity (100%). The specificity (91.25%) was hampered by some false-positive results in recent dengue virus, chikungunya virus, measles virus and human parvovirus B19 infections. The method evaluated is adequate, but the low specificity makes it necessary to consider the clinical and epidemiological contexts of patients, as well as other laboratory results.
Collapse
|
9
|
Bramhachari PV. Advanced Immunotechnological Methods for Detection and Diagnosis of Viral Infections: Current Applications and Future Challenges. Dynamics of Immune Activation in Viral Diseases 2020. [PMCID: PMC7121190 DOI: 10.1007/978-981-15-1045-8_17] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
Diagnosis and identification of viruses is an important component of diagnostic virology laboratory. Although various modes of diagnostic methods are now available at disposal, a vast majority of the diseases across the globe remain undiagnosed. This is largely due to the overlapping undifferentiated set of symptoms across myriad set of RNA and DNA viral diseases. As such, it becomes critical to take into consideration several factors for viral diagnosis ranging from the type and quality of specimen collected, time of specimen collection, mode of transport, accuracy, specificity, sensitivity, and the type of diagnostic method used. This chapter broadly emphasizes various methods on diagnostic virology ranging from the classical methods of diagnosis to the most recently developed molecular methods of detection of virus.
Collapse
|
10
|
|